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tation. Well-known drive line or device
pocket infections, as well as mechanical fail-
ures (also described by Casarotto and col-
leagues1), are not possible with PLV. Anti-
coagulation treatment is avoided, reducing
the risk of bleeding complications. Thrombo-
embolic events caused by clot formation
within the LVAD are also avoided. Further-
more, PLV is much less invasive than LVAD
implantation, and quality of life is enhanced
by avoiding a transcutaneous drive line and
dependence on a mechanical device. Regard-
ing the economic aspect, costs for PLV are
much lower than for LVAD implantation,
and PLV can be performed in many more
hospitals than can LVAD implantation,
which is restricted to specialized centers.
I congratulate Casarotto and col-
leagues1 on their successful management
of this difficult case. However, I encourage
cardiac surgeons to take alternative treat-
ment options such as PLV into consider-
ation in such challenging cases.
Stefan Christiansen, MD
Department of Cardiothoracic Surgery
University of Aachen
Aachen, Germany
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Aortic insufficiency in patients with
Marfan syndrome: A surgical
dilemma
To the Editor:
The excellent article by de Oliveira and
colleagues1 and the related editorial by
Miller2 are vital reading for all those in-
volved in the management of patients with
Marfan syndrome (MFS). In their article,
de Oliveira and colleagues1 reported the
results of surgery for aortic root aneurysm
in patients with MFS. Sixty-one of these
patients underwent aortic valve–sparing
operations, with reimplantation of the aor-
tic valve in 39 patients and remodeling of
the aortic root in 22. Patient age ranged
between 12 and 59 years. Freedom from
reoperation at 10 years was 100%, but only
2 patients had a full 10-year follow-up.
Twenty-one percent of patients required re-
exploration for bleeding (only 3% in the re-
implantation group). Perhaps the most signif-
icant finding was that 25% of patients had
more than 2 aortic insufficiency during the
follow-up period. Thus if aortic insufficiency
continues to progress through a longer fol-
low-up period, reoperation will be necessary
in a significant number of patients.
Histologic evaluation of the leaflets of
the aortic valve has demonstrated four dif-
ferent layers. The subendocardial ventricu-
lar layer is composed of elastic fibers ori-
ented in various directions.3 The
noncoaptational parts of the aortic leaflets
are composed of an elastic grid reinforced
with collagen fibers and bundles. The re-
maining layers have irregular amounts of
arbitrarily oriented elastic fibers and colla-
gen fibers.3 MFS is caused in part by mu-
tations within the gene for fibrillin 1, which
is the main protein of the microfibril net-
work. Microfibrils play a crucial role in the
trophicity and function of elastic tissue.4 In
MFS, these mutations lead to the formation
of thoracic aortic aneurysms5 and appear to
be related to proteolytic degradation.6 If
the progression of aortic insufficiency in de
Oliveira and colleagues’ series1 is due to
causes inherent in the surgical technique,
this problem could probably by prevented by
modifications in the surgical technique.
David has already modified this technique
several times,2 and all these modifications are
included in the cases in this study. If aortic
insufficiency is due to a structural deficiency
of the native aortic leaflets, however, then all
patients are at a potentially high risk for re-
operation.
Kon and associates7 have recently re-
ported the results of root replacement with
the Freestyle bioprosthesis (Medtronic, Inc,
Minneapolis, Minn) in 104 consecutive pa-
tients with multiple etiologies of aortic
valve disease who took part in the world-
wide study for submission to the Food and
Drug Administration for premarket ap-
proval of this valve. Patient age ranged
from 48 to 87 years. Freedom from reop-
eration was 100% at 8 years, with no struc-
tural valve deterioration. More signifi-
TABLE 1. Hemodynamic and echocardiographic parameters before and after
doxorubicin chemotherapy with (group 2) or without (group 1) PLV
Before After 6 wk later
LVEDV (mL)
Group 1 55.7 12.2 65.5 5.7 67.3 5.6
Group 2 54.6 5.0 66.4 4.6 60.2 4.5
LVESV (mL)
Group 1 22.0 6.7 40.6 8.2 46.6 5.3*
Group 2 23.0 2.7 41.5 6.9 34.3 4.9*
Cardiac
output
(L/min)
Group 1 4.0 0.3 3.3 0.1 3.0 0.2*
Group 2 3.9 0.3 3.1 0.2 3.3 0.1*
Ejection fraction (%)
Group 1 61.1 5.1 37.7 5.7 30.5 5.8
Group 2 57.7 9.0 37.2 12.2 42.6 10.5
Oxygen delivery (mL/min)
Group 1 1130 170 790 65 728 111
Group 2 1153 155 765 53 820 95
Oxygen extraction
Group 1 0.12 0.01 0.24 0.01 0.32 0.01*
Group 2 0.13 0.01 0.26 0.01 0.26 0.01*
LVEDV, Left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume.
*P  .05.
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cantly, only 2% had mild aortic
insufficiency. Comparison of these two se-
ries is difficult because of the differences in
population and etiology, but in the absence
of prospective or randomized studies, we
must base our decisions on extrapolation
from current data. Thus there is no conclu-
sive evidence that valve-sparing operations
for patients with MFS have an advantage
relative to Freestyle root replacement. Anti-
mineralization treatment and zero-pressure
fixation8 make this valve more attractive for
implantation than a homograft because of the
lower rate of calcification with no significant
changes in the elastic properties of the elastic
wall,8,9 and reoperation if needed is simpler
with the Freestyle bioprosthesis because of
lessened inflammatory reaction in the host
tissues. A Freestyle root replacement with
graft extension could be a reasonable opera-
tion for patients with MFS for whom antico-
agulation is contraindicated or not accept-
able. Further long term data are needed,
however, before any of these operations can
be recommended with certainty.
Carlos Del Campo, MD
Department of Cardiothoracic Surgery
Western Medical Center Anaheim and
University of California Irvine
Fullerton, CA 92835
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Amiodarone for postoperative atrial
fibrillation
To the Editor:
We read with interest the article by Yagdi
and colleagues1 dealing with the use of
amiodarone to prevent of postoperative
atrial fibrillation (AF). In this prospective,
randomized study, 77 patients (amiodarone
group) received intravenous amiodarone
during the first 48 hours after the operation
followed by declining oral dosing over a
30-day period, and 80 patients (control
group) received placebo. The authors ob-
served a statistically significant reduction
in the incidence of AF (10% in amiodarone
group vs 25% in control group) as well as
a significant reduction in the mean duration
of AF (12.8  4.8 hours in amiodarone
group vs 34.7  28.7 hours in control
group).
We recently reported similar results in a
prospective, randomized study conducted
with 200 consecutive patients undergoing
CABG.2 The treatment group received oral
amiodarone 4 hours after arrival to the in-
tensive care unit and until hospital dis-
charge. The incidence of AF was reduced
from 25% to 12%, and its duration was also
reduced.
These two prospective randomized tri-
als constitute additional evidence for the
efficacy of amiodarone in the prevention of
AF after CABG. Interestingly, although in
our series only the oral form of amiodarone
was used, the results observed were almost
identical to those reported by Yagdi and
colleagues,1 suggesting that the intrave-
nous administration of amiodarone may not
offer additional beneficial effects in pre-
venting postoperative AF. If these observa-
tions were to be confirmed in future stud-
ies, the problem of the cost-effectiveness of
the use of amiodarone in this setting, as
alluded to in the editorial by Saltman,3
would be completely resolved.
Alexander Yazigi, MD
Fadia Haddad, MD
Samia Madi-Jebara, MD
Department of Anesthesiology and Critical
Care
Ghassan Sleilaty, MD
Victor A. Jebara, MD
Department of Cardiovascular and Thoracic
Surgery
Hoˆtel-Dieu de France
Beirut, Lebanon
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Reply to the Editor:
There is no consensus about the optimal
dose and route of amiodarone in prophy-
laxis against atrial fibrillation after coro-
nary artery bypass grafting. In most of the
studies we cited in our article,1 intravenous
amiodarone doses ranged from 10 mg/(kg ·
d) to 20 mg/(kg · d) through 2 to 8 days.
Oral amiodarone doses ranged from 2.8 to
7.0 g through 7 to 20 days. We used rela-
tively short-term, low-dose (10 mg/[kg · d],
for 48 hours) intravenous administration,
followed by oral tapered doses at a total of
9.0 g through 30 days. We prefer a combi-
nation therapy to take the advantage of
accelerated loading time with the intrave-
nous amiodarone and to obtain the incre-
mental benefits of the oral amiodarone
during the short-term intravenous adminis-
tration.
We found that the postoperative admin-
istration of amiodarone was effective at
significantly reducing the incidence of
postoperative atrial fibrillation by 14.6%,
the duration of atrial fibrillation episodes
by 21.9 hours, and the ventricular response
rate by 20 beats/min. In addition to the
lower incidence of postoperative atrial fi-
brillation, the amiodarone group had sig-
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